University of Groningenfounded in 1614  -  top 100 university
Close
How to find us dr. B.D. Westenbrink

dr. B.D. Westenbrink

Cardiologist

No picture available
E-mail:
b.d.westenbrink umcg.nl

Research

Research units:

Advanced
Advanced

Reset

to
1 - 50 out of 69Page size: 50
  1. 2020
  2. Yurista, S. R., Matsuura, T. R., Silljé, H. H. W., Nijholt, K. T., McDaid, K. S., Shewale, S. V., Leone, T. C., Newman, J. C., Verdin, E., van Veldhuisen, D. J., de Boer, R. A., Kelly, D. P., & Westenbrink, B. D. (2020). Ketone Ester Treatment Improves Cardiac Function and Reduces Pathologic Remodeling in Preclinical Models of Heart Failure. Circulation-Heart failure, 14, [e007684]. https://doi.org/10.1161/CIRCHEARTFAILURE.120.007684
  3. Flores-Guerrero, J. L., Westenbrink, B. D., Connelly, M. A., Otvos, J. D., Groothof, D., Shalaurova, I., Garcia, E., Navis, G., de Boer, R. A., Bakker, S. J. L., & Dullaart, R. P. F. (2020). Association of beta-hydroxybutyrate with development of heart failure: Sex differences in a Dutch population cohort. European Journal of Clinical Investigation, 1-11. [13468]. https://doi.org/10.1111/eci.13468
  4. Nollet, E. E., Westenbrink, B. D., de Boer, R. A., Kuster, D. W. D., & van der Velden, J. (2020). Unraveling the Genotype-Phenotype Relationship in Hypertrophic Cardiomyopathy: Obesity-Related Cardiac Defects as a Major Disease Modifier. Journal of the American Heart Association, 9(22), e018641. https://doi.org/10.1161/JAHA.120.018641
  5. Withaar, C., Meems, L. M. G., Markousis-Mavrogenis, G., Boogerd, C. J., Silljé, H. H. W., Schouten, E. M., Dokter, M. M., Voors, A. A., Westenbrink, B. D., Lam, C. S. P., & de Boer, R. A. (2020). The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of Heart Failure with Preserved Ejection Fraction. Cardiovascular Research. https://doi.org/10.1093/cvr/cvaa256
  6. van Veldhuisen, D. J., van Woerden, G., Gorter, T. M., van Empel, V. P. M., Manintveld, O. C., Tieleman, R. G., Maass, A. H., Vernooy, K., Westenbrink, B. D., van Gelder, I. C., & Rienstra, M. (2020). Ventricular Tachyarrhythmia Detection by Implantable Loop Recording in Patients with Heart Failure and Preserved Ejection Fraction: The VIP-HF study. European Journal of Heart Failure, (10), 1923-1929. https://doi.org/10.1002/ejhf.1970
  7. Hoes, M. F., te Riele, A. S. J. M., Gladka, M. M., Westenbrink, B. D., van Hout, G. P. J., van den Hoogenhof, M. M. G., Ghigo, A., Bollini, S., Purcell, N. H., Sohaib, S. M. A., Kardys, I., & Kuster, D. W. D. (2020). Young@Heart: empowering the next generation of cardiovascular researchers. Netherlands Heart Journal, 28(SUPPL 1), S25-30. https://doi.org/10.1007/s12471-020-01454-6
  8. Yurista, S. R., Sillje, H. H. W., Nijholt, K. T., Dokter, M. M., van Veldhuisen, D. J., de Boer, R. A., & Westenbrink, B. D. (2020). Correction to: Factor Xa Inhibition with Apixaban Does Not Influence Cardiac Remodelling in Rats with Heart Failure After Myocardial Infarction (vol 53, pg 861, 2020). Cardiovascular Drugs and Therapy. https://doi.org/10.1007/s10557-020-07029-2
  9. Yurista, S., Sillje, H., van Goor, H., Hillebrands, J-L., Heerspink, H. J. L., de Menezes Montenegro, L., Oberdorf, S., Boer, de, R., & Westenbrink, D. (2020). Effects of Sodium-Glucose Co-transporter 2 Inhibition with Empaglifozin on Renal Structure and Function in Non-diabetic Rats with Left Ventricular Dysfunction After Myocardial Infarction. Cardiovascular Drugs and Therapy, 34(3), 311-321. https://doi.org/10.1007/s10557-020-06954-6
  10. Klimczak-Tomaniak, D., Bouwens, E., Schuurman, A-S., Akkerhuis, K. M., Constantinescu, A., Brugts, J., Westenbrink, B. D., van Ramshorst, J., Germans, T., Paczek, L., Umans, V., Boersma, E., & Kardys, I. (2020). Temporal patterns of macrophage- and neutrophil-related markers are associated with clinical outcome in heart failure patients. ESC Heart Failure, 7(3), 1190-1200. https://doi.org/10.1002/ehf2.12678
  11. Yurista, S., Sillje, H., Nijholt, K., Dokter, M., van Veldhuisen, D. J., Boer, de, R., & Westenbrink, D. (2020). Factor Xa Inhibition with Apixaban Does Not Influence Cardiac Remodelling in Rats with Heart Failure After Myocardial Infarction. Cardiovascular Drugs and Therapy. https://doi.org/10.1007/s10557-020-06999-7
  12. Westenbrink, B. D., de Boer, R. A., & Vliegenthart, R. (2020). Aortic regurgitation, a forgotten valve disease in hypertrophic cardiomyopathy? European Journal of Radiology, 126, [108971]. https://doi.org/10.1016/j.ejrad.2020.108971
  13. Yurista, S., Sillje, H., Rienstra, M., Boer, de, R., & Westenbrink, D. (2020). Sodium-glucose co-transporter 2 inhibition as a mitochondrial therapy for atrial fibrillation in patients with diabetes? Cardiovascular Diabetology, 19(1), 5. [5]. https://doi.org/10.1186/s12933-019-0984-0
  14. 2019
  15. van Woerden, G., van Veldhuisen, D. J., Rienstra, M., & Westenbrink, B. D. (2019). Myocardial adiposity in heart failure with preserved ejection fraction: the plot thickens. European Journal of Heart Failure, 22, 455-457. https://doi.org/10.1002/ejhf.1653
  16. Yurista, S. R., Silljé, H. H. W., Oberdorf-Maass, S. U., Schouten, E-M., Pavez Giani, M. G., Hillebrands, J-L., van Goor, H., van Veldhuisen, D. J., de Boer, R. A., & Westenbrink, B. D. (2019). Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction. European Journal of Heart Failure, 21(7), 862-873. https://doi.org/10.1002/ejhf.1473
  17. 2018
  18. van Woerden, G., Gorter, T. M., Westenbrink, B. D., Willems, T. P., van Veldhuisen, D. J., & Rienstra, M. (2018). Epicardial fat in heart failure patients with mid-range and preserved ejection fraction. European Journal of Heart Failure, 20(11), 1559-1566. https://doi.org/10.1002/ejhf.1283
  19. Tromp, J., Westenbrink, B. D., Ouwerkerk, W., van Veldhuisen, D. J., Samani, N. J., Ponikowski, P., Metra, M., Anker, S. D., Cleland, J. G., Dickstein, K., Filippatos, G., van der Harst, P., Lang, C. C., Ng, L. L., Zannad, F., Zwinderman, A. H., Hillege, H. L., van der Meer, P., & Voors, A. A. (2018). Identifying Pathophysiological Mechanisms in Heart Failure With Reduced Versus Preserved Ejection Fraction. Journal of the American College of Cardiology, 72(10), 1081-1090. https://doi.org/10.1016/j.jacc.2018.06.050
  20. Meijers, W. C., Maglione, M., Bakker, S. J. L., Oberhuber, R., Kieneker, L. M., de Jong, S., Haubner, B. J., Nagengast, W. B., Lyon, A. R., van der Vegt, B., van Veldhuisen, D. J., Westenbrink, B. D., van der Meer, P., Silljé, H. H. W., & de Boer, R. A. (2018). Heart Failure Stimulates Tumor Growth by Circulating Factors. Circulation, 138(7), 678-691. https://doi.org/10.1161/CIRCULATIONAHA.117.030816
  21. van der Meer, P., Grote Beverborg, N., Pfeffer, M. A., Olson, K., Anand, I. S., Westenbrink, B. D., McMurray, J. J. V., Swedberg, K., Young, J. B., Solomon, S. D., & van Veldhuisen, D. J. (2018). Hyporesponsiveness to Darbepoetin Alfa in Patients With Heart Failure and Anemia in the RED-HF Study (Reduction of Events by Darbepoetin Alfa in Heart Failure) Clinical and Prognostic Associations. Circulation-Heart failure, 11(2), [004431]. https://doi.org/10.1161/CIRCHEARTFAILURE.117.004431
  22. 2017
  23. van Vark, L. C., Lesman-Leegte, I., Baart, S. J., Postmus, D., Pinto, Y. M., Orsel, J. G., Westenbrink, B. D., Brunner-la Rocca, H. P., van Miltenburg, A. J. M., Boersma, E., Hillege, H. L., Akkerhuis, K. M., & TRIUMPH Investigators (2017). Prognostic Value of Serial ST2 Measurements in Patients With Acute Heart Failure. Journal of the American College of Cardiology, 70(19), 2378-2388. https://doi.org/10.1016/j.jacc.2017.09.026
  24. Westenbrink, B. D. D., Nijholt, K. T., De Boer, R. A., Van de Kolk, C. W. A., Van Gilst, W. H., Sillje, H. H. W., & Booij, H. G. (2017). AKIP1 promotes physiological cardiac hypertrophy. European Journal of Heart Failure, 19, 332.
  25. Westenbrink, B. D., Alings, M., Granger, C. B., Alexander, J. H., Lopes, R. D., Hylek, E. M., Thomas, L., Wojdyla, D. M., Hanna, M., Keltai, M., Steg, P. G., De Caterina, R., Wallentin, L., & van Gilst, W. H. (2017). Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. American Heart Journal, 185, 140-149. https://doi.org/10.1016/j.ahj.2016.12.008
  26. Gray, C. B. B., Suetomi, T., Xiang, S., Mishra, S., Blackwood, E. A., Glembotski, C. C., Miyamoto, S., Westenbrink, B. D., & Brown, J. H. (2017). CaMKII delta subtypes differentially regulate infarct formation following ex vivo myocardial ischemia/reperfusion through NF-kappa B and TNF-alpha. Journal of molecular and cellular cardiology, 103, 48-55. https://doi.org/10.1016/j.yjmcc.2017.01.002
  27. Booij, H. G., Koning, A. M., van Goor, H., de Boer, R. A., & Westenbrink, B. D. (2017). Selecting heart failure patients for metabolic interventions. Expert review of molecular diagnostics, 17(2), 141-152. https://doi.org/10.1080/14737159.2017.1266939
  28. 2016
  29. Booij, H. G., Yu, H., De Boer, R. A., van de Kolk, C. W. A., Sluis, van de, B., van Deursen, J. M., Van Gilst, W. H., Sillje, H. H. W., & Westenbrink, B. D. (2016). Overexpression of A kinase interacting protein 1 attenuates myocardial ischemia / reperfusion injury, but does not influence heart failure development. Cardiovascular Research, 111(3), 217-226. https://doi.org/10.1093/cvr/cvw161
  30. Westenbrink, B. D., Brugts, J. J., McDonagh, T. A., Filippatos, G., Ruschitzka, F., & van Laake, L. W. (2016). Heart failure specialization in Europe. European Journal of Heart Failure, 18(4), 347-349. https://doi.org/10.1002/ejhf.506
  31. Westenbrink, B. D., van Laake, L. W., & Brugts, J. J. (2016). The Postgraduate Course in Heart Failure. European Heart Journal, 37(5), 428-429. https://doi.org/10.1093/eurheartj/ehv681
  32. 2015
  33. Booij, H. G., Damman, K., Warnica, J. W., Rouleau, J. L., van Gilst, W. H., & Westenbrink, B. D. (2015). beta-blocker Therapy is Not Associated with Reductions in Angina or Cardiovascular Events After Coronary Artery Bypass Graft Surgery: Insights from the IMAGINE Trial. Cardiovascular Drugs and Therapy, 29(3), 277-285. https://doi.org/10.1007/s10557-015-6600-y
  34. Karper, J. C., & Westenbrink, B. D. (2015). BNP in heart failure: even leucocytes cannot escape its influence. European Journal of Heart Failure, 17(6), 536-538. https://doi.org/10.1002/ejhf.295
  35. Westenbrink, B. D., Alings, M., Connolly, S. J., Eikelboom, J., Ezekowitz, M. D., Oldgren, J., Yang, S., Pongue, J., Yusuf, S., Wallentin, L., & van Gilst, W. H. (2015). Anemia predicts thromboembolic events, bleeding complications and mortality in patients with atrial fibrillation: insights from the RE-LY trial. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 13(5), 699-707. https://doi.org/10.1111/jth.12874
  36. Westenbrink, B. D., & Kingma, J. H. (2015). Chagas, a cardiomyopathy emerging from obscurity. European Journal of Heart Failure, 17(4), 355-357. https://doi.org/10.1002/ejhf.261
  37. Maass, A. H., & Westenbrink, B. D. (2015). Cardiac resynchronization therapy in mild heart failure should be reserved for true dyssynchronopathy. European Journal of Heart Failure, 17(3), 239-241. https://doi.org/10.1002/ejhf.251
  38. Westenbrink, B. D., Ling, H., Divakaruni, A. S., Gray, C. B. B., Zambon, A. C., Dalton, N. D., Peterson, K. L., Gu, Y., Matkovich, S. J., Murphy, A. N., Miyamoto, S., Dorn, G. W., & Brown, J. H. (2015). Mitochondrial Reprogramming Induced by CaMKII delta Mediates Hypertrophy Decompensation. Circulation research, 116(5), E28-E39. https://doi.org/10.1161/CIRCRESAHA.116.304682
  39. Tigchelaar, W., Yu, H., De Jong, A. M., van Gilst, W. H., van der Harst, P., Westenbrink, B. D., de Boer, R. A., & Sillje, H. H. W. (2015). Loss of mitochondrial exo/endonuclease EXOG affects mitochondrial respiration and induces ROS mediated cardiomyocyte hypertrophy. American journal of physiology-Cell physiology, 308(2), C155-C163. https://doi.org/10.1152/ajpcell.00227.2014
  40. 2014
  41. van Oort, R. J., Brown, J. H., & Westenbrink, B. D. (2014). CaMKII confirms its promise in ischaemic heart disease. European Journal of Heart Failure, 16(12), 1268-1269. https://doi.org/10.1002/ejhf.204
  42. Kleijn, L., Westenbrink, B. D., van Deursen, V. M., Damman, K., de Boer, R. A., Hillege, H., van Veldhuisen, D. J., Voors, A. A., & van der Meer, P. (2014). Anemia is associated with an increased central venous pressure and mortality in a broad spectrum of cardiovascular patients. Clinical Research in Cardiology, 103(6), 467-476. https://doi.org/10.1007/s00392-014-0673-7
  43. de Boer, R., Ruifrok, W. P., Meems, L. M. G., Maass, A. H., Westenbrink, B. D., van Gilst, W. H., & Sillje, H. H. W. (2014). Genetic disruption of erythropoietin-receptor impairs exercise tolerance due to cardiac and muscle maladaptation. European Journal of Heart Failure, 16, 100-100.
  44. Liu, L. C. Y., Damman, K., Lipsic, E., Maass, A. H., Rienstra, M., & Westenbrink, B. D. (2014). Heart failure highlights in 2012-2013. European Journal of Heart Failure, 16(2), 122-132. https://doi.org/10.1002/ejhf.43
  45. 2013
  46. Yin, M., Westenbrink, B. D., Meissner, M., van Gilst, W. H., & de Boer, R. A. (2013). Variable effects of anti-diabetic drugs in animal models of myocardial ischemia and remodeling: A translational perspective for the cardiologist. International Journal of Cardiology, 169(6), 385-393. https://doi.org/10.1016/j.ijcard.2013.10.005
  47. Yu, H., Tigchelaar, W., Koonen, D. P. Y., Patel, H. H., de Boer, R. A., van Gilst, W. H., Westenbrink, B. D., & Sillje, H. H. W. (2013). AKIP1 expression modulates mitochondrial function in rat neonatal cardiomyocytes. PLoS ONE, 8(11), [e80815]. https://doi.org/10.1371/journal.pone.0080815
  48. Yu, H., Tigchelaar, W., Lu, B., van Gilst, W. H., de Boer, R. A., Westenbrink, B. D., & Sillje, H. H. W. (2013). AKIP1, a Cardiac Hypertrophy Induced Protein that Stimulates Cardiomyocyte Growth via the Akt Pathway. International Journal of Molecular Sciences, 14(11), 21378-21393. https://doi.org/10.3390/ijms141121378
  49. Westenbrink, B. D., Kleijn, L., & van der Meer, P. (2013). Haemodilution is a mechanism of anaemia in patients with heart failure: reply. European Journal of Heart Failure, 15(9), 1074-1075. https://doi.org/10.1093/eurjhf/hft131
  50. Westenbrink, B. D., Edwards, A. G., McCulloch, A. D., & Brown, J. H. (2013). The promise of CaMKII inhibition for heart disease: preventing heart failure and arrhythmias. EXPERT OPINION ON THERAPEUTIC TARGETS, 17(8), 889-903. https://doi.org/10.1517/14728222.2013.809064
  51. Westenbrink, B. D., Edwards, A. G., & Miyamoto, S. (2013). Conference report from the 2012 AHA scientific sessions in Los Angeles. EXPERT OPINION ON THERAPEUTIC TARGETS, 17(6), 733-737. https://doi.org/10.1517/14728222.2013.794791
  52. Kleijn, L., Westenbrink, B. D., & van der Meer, P. (2013). Erythropoietin and heart failure: the end of a promise? European Journal of Heart Failure, 15(5), 479-481. https://doi.org/10.1093/eurjhf/hft058
  53. Mahmud, H., Ruifrok, W. P. T., Westenbrink, B. D., Cannon, M. V., Vreeswijk-Baudoin, I., van Gilst, W. H., Sillje, H. H. W., & de Boer, R. A. (2013). Suicidal erythrocyte death, eryptosis, as a novel mechanism in heart failure-associated anaemia. Cardiovascular Research, 98(1), 37-46. https://doi.org/10.1093/cvr/cvt010
  54. Westenbrink, B. D., & Dorn, G. W. (2013). Imaging the cardiac diet. European Journal of Heart Failure, 15(2), 123-124. https://doi.org/10.1093/eurjhf/hfs211
  55. 2012
  56. Westenbrink, B. D., Damman, K., Rienstra, M., Maass, A. H., & van der Meer, P. (2012). Heart failure highlights in 2011. European Journal of Heart Failure, 14(10), 1090-1096. https://doi.org/10.1093/eurjhf/hfs121
  57. 2011
  58. Westenbrink, B. D., Kremer Hovinga, T., Kloppenburg, W., Veeger, N. J., & Janssen, W. (2011). B-type natriuretic peptide and interdialytic fluid retention are independent and incremental predictors of mortality in hemodialysis patients. CLINICAL NEPHROLOGY, 76(5), 373-379. https://doi.org/10.5414/CN106858
  59. Westenbrink, B. D., Kleijn, L., de Boer, R. A., Tijssen, J. G., Warnica, W. J., Baillot, R., Rouleau, J. L., van Gilst, W. H., & IMAGINE Investigators (2011). Sustained postoperative anaemia is associated with an impaired outcome after coronary artery bypass graft surgery: insights from the IMAGINE trial. Heart, 97(19), 1590-1596. https://doi.org/10.1136/heartjnl-2011-300118
  60. 2010
  61. Damman, K., Van Veldhuisen, D. J., Navis, G., Vaidya, V. S., Smilde, T. D. J., Westenbrink, B. D., Bonventre, J. V., Voors, A. A., & Hillege, H. L. (2010). Tubular damage in chronic systolic heart failure is associated with reduced survival independent of glomerular filtration rate. Heart, 96(16), 1297-1302. https://doi.org/10.1136/hrt.2010.194878
Previous 1 2 Next

ID: 219049

University of Groningen staff: edit these data

print
Follow the UGfacebook twitter linkedin rss instagram youtube